Press Releases

Dr Gerry Murphy is appointed as a non-executive director and Chairman-designate of the Company.

This document has subsequently been updated and published on the 5 November 2015. Please follow this link for the updated comparative financial information.

Tate & Lyle issues the following routine trading update including comments on sweetener pricing negotiations and a statement on Western Sugar. Current Financial YearUnderlying trading in the Group for the 9 months to 31 December 2001 has continued to be in line with plan and significantly ahead of...

Please download the PDF to access the announcement.

Tate & Lyle Ventures announces today that it will invest in UK-based marine biotechnology company, Aquapharm Biodiscovery Ltd (Aquapharm). Tate & Lyle Ventures forms part of a consortium which has invested second round funding of £4.0m. Aquapharm develops natural products from the microbial resource...

A strong start to the year announced in our Q1 2016 Trading Statement supporting confidence in full year.

ACCOUNTING FOR JOINT VENTURES With effect from 1 April 2014, Tate & Lyle adopted IFRS 11 ‘Joint Arrangements’ which will change significantly the basis of accounting for its interests in joint ventures. Previously, the Group’s interests in joint ventures were accounted for by proportionate...

Tate & Lyle, a global leader in renewable ingredients, today announces the launch of Yoghurt REBALANCE™ 006 and 007. These are new Solution Sets for food industry customers created to fulfil European consumer-demand for fat-free, reduced energy, reduced sugars yoghurts. Yoghurt REBALANCE™ 006 and...

Tate & Lyle PLC announces that despite expressions of interest from a number of parties and several weeks of detailed negotiations, the sale process has not produced an offer for its world-wide molasses and storage business ("UM") that reflects its contribution to the Group. UM continues to trade...

Tate & Lyle PLC (“the Company”) announces that, on Friday 1 August 2003, Mr Stuart Strathdee, an executive director of the Company, was allotted 3,522 ordinary shares in the Company on the exercise of a Sharesave option. The option price was 220p. Mr Strathdee now has an interest in 34,920 ordinary...